Salute e Benessere

Illuccix® Approved in Denmark

PSMA-PET imaging[2] represents a significant advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT[3] scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)[4]. Illuccix PSMA-PET will help fulfil a critical unmet need by facilitating access to timely and effective…
PR Newswire
11/02/2025

Dr Massimo Cristofanilli, MD Joins Datar Cancer Genetics as Strategic Advisor

Dr. Cristofanilli has an esteemed career with over 400 scientific publications on cancer biomarkers, liquid biopsy, and targeted therapies. He is a past President of the International Society of Liquid Biopsy (ISLB). Dr. Cristofanilli has an esteemed career with over 400 scientific publications on cancer biomarkers, liquid biopsy, and targeted therapies. He is a past President of the International Society of Liquid Biopsy (ISLB). "It is my pleasure to take up this role," said Dr....
PR Newswire
11/02/2025

ILIKOS Consulting Group and Jordan Center for Pharmaceutical Research (JCPR)…

As the timelines for developing new therapies or technologies grow longer and the competitive landscape becomes increasingly high-risk, exploring emerging regions offering high quality, digestible cost and effective recruitment is essential. For the generics industry, numerous cross-regional challenges have also emerged: evolving regulatory requirements, data standardization, and cost pressures. As the timelines for developing new therapies or technologies grow longer and the competitive...
PR Newswire
11/02/2025

Large Swedish healthcare region expands use of Sectra's solution with digital…

Region Västra Götaland is a healthcare region in the southwest of Sweden. It provides care to approximately 1.7 million people through 17 hospitals, with pathology laboratories at three locations in the region (Gothenburg, Borås and Trollhättan). Sectra's digital pathology solution will allow their pathologists to enhance review and collaboration around cases as well as benefit from tightly integrated AI tools. The digital workflow provides instant and, when needed, remote access to digital…
PR Newswire
11/02/2025

Dr Massimo Cristofanilli, MD Joins Datar Cancer Genetics as Strategic Advisor

Dr. Cristofanilli has an esteemed career with over 400 scientific publications on cancer biomarkers, liquid biopsy, and targeted therapies. He is a past President of the International Society of Liquid Biopsy (ISLB). Dr. Cristofanilli has an esteemed career with over 400 scientific publications on cancer biomarkers, liquid biopsy, and targeted therapies. He is a past President of the International Society of Liquid Biopsy (ISLB). "It is my pleasure to take up this role," said Dr....
PR Newswire
11/02/2025

Roquette Reshapes the Pharmaceutical Coating Landscape with an Innovative and…

Roquette Reshapes the Pharmaceutical Coating Landscape with an Innovative and High-Performance PlatformLille – 11 February 2025- Roquette launches a new coatings platform, combining cutting-edge performance with eco-consciousness, designed to meet the growing demand in prescription pharmaceutical, nutraceutical, and OTC markets. With this game-changing platform, Roquette now offers one of the widest excipient portfolios on the market, with reliable, high-quality options to meet...
Nasdaq GlobeNewswire
11/02/2025

PureHealth Reports Record Revenue of AED 25.8 Billion and 78% Net Profit Growth…

Shaista Asif, Group Chief Executive Officer at PureHealth, said: "2024 has been a transformative year for PureHealth, marked by strategic expansion, operational excellence, and innovation – where we pushed boundaries and redefined healthcare possibilities. With the acquisition of Circle Health Group in the UK, we extended our world-class care beyond borders, while the integration of Sheikh Shakhbout Medical City (SSMC) reinforced our expertise in complex, life-saving treatments. Every…
PR Newswire
11/02/2025

EssilorLuxottica acquires the Canadian med-tech start-up Cellview

EssilorLuxottica acquires the Canadian med-tech start-up Cellview The company's ultra-widefield proprietary technology allows for fast and easy high-quality images, providing a comprehensive view of the retinaParis, France (11 February 2025)– Furthering its commitment to elevating industry standards and enhancing the quality of vision care, EssilorLuxottica has acquired Cellview Imaging Inc, a Canadian start-up specialized in innovative diagnostic via retinal imaging. With the...
Nasdaq GlobeNewswire
11/02/2025

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire…

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in Phase 3 development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillationAcquisition adds a late-stage asset and is aligned with Novartis strategic focus, strength and expertise in the cardiovascular therapeutic area...
Nasdaq GlobeNewswire
11/02/2025

Novonesis to acquire dsm-firmenich's share of the Feed Enzyme Alliance

Novonesis has reached an agreement with dsm-firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities, in exchange for a total cash consideration of EUR 1.5 billion. After more than 25 years of successful collaboration, a strategic repositioning at dsm-firmenich allowed this opportunity to materialize. This acquisition is aligned with Novonesis' growth strategy and expands its presence across the animal biosolutions value chain. Financially, this...
Nasdaq GlobeNewswire
11/02/2025

Novonesis to acquire dsm-firmenich's share of the Feed Enzyme Alliance

Novonesis has reached an agreement with dsm-firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities, in exchange for a total cash consideration of EUR 1.5 billion. After more than 25 years of successful collaboration, a strategic repositioning at dsm-firmenich allowed this opportunity to materialize. This acquisition is aligned with Novonesis' growth strategy and expands its presence across the animal biosolutions value chain. Financially, this...
Nasdaq GlobeNewswire
11/02/2025

XRPH AI App Goes Live - Instant Multilingual Medical Guidance at Users'…

The XRPH AI App is more than just a medical tool—it's an intelligent health companion powered by advanced AI, capable of understanding and responding in multiple languages, ensuring accessibility across diverse communities. Whether you seek traditional medical advice or holistic wellness guidance, XRPH AI has you covered. The XRPH AI App is more than just a medical tool—it's an intelligent health companion powered by advanced AI, capable of understanding and responding in multiple languages,...
PR Newswire
11/02/2025

American Association for Cancer Research Annual Meeting 2025: Stay Ahead with…

The 2025 American Association for Cancer Research Meeting will highlight groundbreaking research, with more details on presenting companies to be shared closer to the event. Key dates to remember include: The 2025 American Association for Cancer Research Meeting will highlight groundbreaking research, with more details on presenting companies to be shared closer to the event. Key dates to remember include: Leverage the AACR 2025 Conversation: Stay Tuned for How We Can Help AACR Conference...
PR Newswire
10/02/2025

Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in…

Ariel, a 35-year-old elderly female donkey residing at a rescue farm, had endured years of carrying excessive weight, leading to debilitating osteoarthritis across multiple joints. The chronic pain severely limited her mobility, affecting her overall well-being. Ariel, a 35-year-old elderly female donkey residing at a rescue farm, had endured years of carrying excessive weight, leading to debilitating osteoarthritis across multiple joints. The chronic pain severely limited her mobility,...
PR Newswire
10/02/2025

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a…

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million structured financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early January 2025 and randomization of the last patient expected within the first half of 2025Pipeline prioritization plan presented to the workers council to focus exclusively on...
Nasdaq GlobeNewswire
10/02/2025

UCKG: THREE IN FOUR GEN Z URGE GOVERNMENT TO PARTNER WITH FAITH GROUPS AND…

Commissioned by the Universal Church of the Kingdom of God (UCKG) with research conducted by Research Without Barriers, the report surveyed over 2,000 UK adults. It highlights growing public confidence in faith groups' capacity to meet social needs, particularly among younger generations. Commissioned by the Universal Church of the Kingdom of God (UCKG) with research conducted by Research Without Barriers, the report surveyed over 2,000 UK adults. It highlights growing public confidence in...
PR Newswire
10/02/2025

Press Release: Transparency Notification from Shareholders

Transparency Notification from ShareholdersGhent, Belgium – 10 February 2025 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entities listed below, notifying the number of voting rights attached to the shares mentioned next to their name in the table below. Reason for...
Nasdaq GlobeNewswire
10/02/2025

Notification of managers' transactions

ANNOUNCEMENT NO. 288 10 February 2025Notification of managers' transactionsChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of the Chair of ChemoMetec's Board of Directors Niels Thestrup in the attached PDF document.For further...
Nasdaq GlobeNewswire
10/02/2025

Pen Needles Market to Hit USD 3.08 Billion by 2030 with 9.2% CAGR |…

Browse in-depth TOC on 'Pen Needles Market' Browse in-depth TOC on 'Pen Needles Market' 200 - Tables 80 - Figures 300 - Pages In this report, the pen needles market has been segmented on the basis of type, length, application, mode of purchase, setting and region. The pen needles market is segmented into standard pen needles and safety pen needles on the basis of type. Standard pen needles are budget-friendly needles for insulin delivery, which explains their popularity in...
PR Newswire
10/02/2025

KFSHRC Detects 276 Fetal Genetic Disorders Through Prenatal Care Saving SAR 360…

RIYADH, Saudi Arabia, Feb.10, 2025(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is enhancing prenatal care through innovation and precision medicine. By testing more than 300 genes, KFSHRC has provided early insights to 1,104 pregnant women, preventing 276 genetic disorders and saving the Saudi healthcare system 360 million riyals.KFSHRC's Preventive Fetal Screening Program identifies genetic risks and ensures targeted care during critical...
Nasdaq GlobeNewswire
10/02/2025

Boehringer's nerandomilast meets primary endpoint in Phase III study…

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 versus placeboThe FIBRONEER™-ILD trial is the second Phase III trial in which the investigational compound nerandomilast has met its primary endpoint 1 Initial safety and tolerability results of the FIBRONEER™-trials are generally consistent with the Phase II results in IPF; full efficacy and...
Nasdaq GlobeNewswire
10/02/2025

Norlase Appoints Jacob Philipsen as Chairman of the Board of Directors

"As a co-founder of Norlase, Jacob was essential in putting the initial team together and has helped guide Norlase as a Board Member ever since," said Oliver Hvidt, CEO and Co-Founder of Norlase. "With his extensive executive experience from deeptech and medtech scale-up companies, Jacob is the perfect Chairman for the next phase of Norlase's growth journey." "As a co-founder of Norlase, Jacob was essential in putting the initial team together and has helped guide…
PR Newswire
10/02/2025

Save the Date: Orion's Capital Markets Day on 22 May 2025

ORION CORPORATIONINVESTOR NEWS10 FEBRUARY 2025 at 14.00 EET Save the Date: Orion's Capital Markets Day on 22 May 2025 Orion will hold a Capital Markets Day for analysts, institutional investors, bankers and media representatives in Helsinki on 22 May 2025 in the afternoon.During the afternoon, Orion's President & CEO, Liisa Hurme, CFO René Lindell, and other members of the Executive Management Board will discuss Orion's growth strategy, financial objectives...
Nasdaq GlobeNewswire
10/02/2025

AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Celiac Disease…

The MosaiQ AiPlex CD multiplex assay, which received IVDR-CE mark certification in August 2024, is designed to improve the accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows. The assay enables a syndromic approach. The MosaiQ AiPlex CD multiplex assay, which receivedIVDR-CE mark certification inAugust 2024, is designed to improve the accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows. The assay enables a syndromic...
PR Newswire
10/02/2025
Altri  Comunicati